Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule

Exclusion Criteria

• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• •Administration of a vaccine not foreseen by the study protocol within 14 days (killed vaccine) or 30 days (attenuated/ live vaccine) before the first vaccine dose.
• •Concurrently participating in another clinical study or exposure to an investigational or a non-investigational product (pharmaceutical product or device).
• •History of hepatitis B infection.
• •Known exposure to hepatitis B virus within 6 months.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• •Pregnant or lactating female.
• •Female planning to become pregnant or planning to discontinue contraceptive precautions.